Impact of 10-day decitabine vs standard intensive chemotherapy on HRQoL in older patients with AML

At 2 months, treatment with 10-day decitabine resulted in a lower risk of HRQoL deterioration compared with intensive chemotherapy (76% vs 88%; odds ratio, 0.43; 95% confidence interval, 0.24–0.76; p = 0.003). 

There were no statistically significant differences in the risk of HRQoL deterioration between decitabine and intensive chemotherapy after 6 or 12 months, suggesting both treatments have comparable long-term impacts on quality of life. 

Patients in the 3+7 arm who underwent allogeneic hematopoietic stem cell transplantation experienced clinically meaningful deterioration post-transplantation, relative to baseline, in the physical functioning, role functioning, fatigue, and burden of illness scales. In contrast, no clinically meaningful deteriorations were observed post-transplantation in the decitabine arm.